A prospective, randomized, open-label, pilot study to compare the effect on carotid atherosclerosis of a tacrolimus-based regimen with conversion from a tacrolimus- to a sirolimus-based regimen at 3-4 months post-transplant in de novo renal transplant recipients.
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Sirolimus (Primary) ; Mycophenolate mofetil; Mycophenolate sodium; Prednisone; Tacrolimus
- Indications Renal transplant rejection
- Focus Biomarker; Pharmacodynamics
- Sponsors Pfizer
- 23 May 2012 Actual initiation date changed from Mar 2006 to Apr 2006 as reported by ClinicalTrials.gov.
- 23 May 2012 Planned end date changed from 1 Mar 2013 to 1 Jan 2012 as reported by ClinicalTrials.gov.
- 23 May 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.